Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Surg Oncol Clin N Am. 2012 Oct;21(4):577-97. doi: 10.1016/j.soc.2012.07.013.

Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy.

Author information

  • 1Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Genk 3600, Belgium. kurt.vanderspeeten@zol.be


Peritoneal surface malignancy is a common manifestation of intra-abdominal malignancies. Systemic chemotherapy offers no long-term survival and poor quality of life for these patients in their terminal stages of disease. By contrast, cytoreductive surgery combined with perioperative intraperitoneal and intravenous chemotherapy has resulted in encouraging clinical results. Further improvements should come from both clinical phase II/III studies and pharmacologic research. This article reviews the current pharmacologic data and controversies regarding the perioperative intraperitoneal and intravenous application of chemotherapy.

Copyright © 2012 Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk